LWANC
CRSP icon

Laurel Wealth Advisors (North Carolina)’s CRISPR Therapeutics CRSP Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$3.94K – 707
2024
Q4 		$3.94K Buy
+100
New +$4.72K ﹤0.01% 579
2022
Q3 		– Sell
-100
Closed -$6K – 555
2022
Q2 		$6K Buy
+100
New +$5.88K ﹤0.01% 420

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s CRSP Position: Q1 2025 in Review

Laurel Wealth Advisors (North Carolina) sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 100 shares — an estimated $3.94K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in CRSP in Q2 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 397 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Laurel Wealth Advisors (North Carolina) reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 100 CRISPR Therapeutics shares in Q1 2025, an estimated $3.94K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 2 quarters.
  • Laurel Wealth Advisors (North Carolina)'s CRISPR Therapeutics position peaked at $6K in Q2 2022.
  • 397 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2025, filed 15 Apr 2025.